New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
10:35 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho said the final CMS pricing for Myriad's BRCA testing represents a cut of about 20%, but that is still less severe than originally outlined. The firm raised its price target on Myriad Genetics to $40 following the ruling, but maintains its Neutral rating on the stock.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
09:50 EDTMYGNLeerink to hold next-generation sequencing meeting
Subscribe for More Information
07:12 EDTMYGNAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
May 3, 2015
17:19 EDTMYGNMyriad Genetics CEO 'actively' searching for acquisitions, WSJ says
In a Wall Street Journal interview, Myriad (MYGN) CEO Mark Capone said the company is currently developing tests for diabetes, autoimmune disorders, and neuropsychiatric conditions, while also "actively looking" for acquisitions. In a separate interview, Robert McDonough, head of Aetna's (AET) clinical policy research, remarked that Myriad should "eventually" be able to have its Vectra DA rheumatoid arthritis test covered by insurance. Reference Link
April 21, 2015
06:40 EDTMYGNStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use